These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 34584911)
41. Adeno-associated virus-mediated gene transfer for hemophilia B. High KA Int J Hematol; 2002 Nov; 76(4):310-8. PubMed ID: 12463593 [TBL] [Abstract][Full Text] [Related]
42. Persistent expression of canine factor IX in hemophilia B canines. Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718 [TBL] [Abstract][Full Text] [Related]
43. Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A. Lytle AM; Brown HC; Paik NY; Knight KA; Wright JF; Spencer HT; Doering CB Mol Ther Methods Clin Dev; 2016; 3():15056. PubMed ID: 26909355 [TBL] [Abstract][Full Text] [Related]
44. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318 [TBL] [Abstract][Full Text] [Related]
45. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Kootstra NA; Matsumura R; Verma IM Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905 [TBL] [Abstract][Full Text] [Related]
46. Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors. Miao CH Thromb J; 2016; 14(Suppl 1):41. PubMed ID: 27766066 [TBL] [Abstract][Full Text] [Related]
47. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Brunetti-Pierri N; Nichols TC; McCorquodale S; Merricks E; Palmer DJ; Beaudet AL; Ng P Hum Gene Ther; 2005 Jul; 16(7):811-20. PubMed ID: 16000063 [TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906 [TBL] [Abstract][Full Text] [Related]
49. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533 [TBL] [Abstract][Full Text] [Related]
50. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Scallan CD; Lillicrap D; Jiang H; Qian X; Patarroyo-White SL; Parker AE; Liu T; Vargas J; Nagy D; Powell SK; Wright JF; Turner PV; Tinlin SJ; Webster SE; McClelland A; Couto LB Blood; 2003 Sep; 102(6):2031-7. PubMed ID: 12738670 [TBL] [Abstract][Full Text] [Related]
51. Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo. Madsen DE; Nichols TC; Merricks EP; Waters EK; Wiinberg B PLoS One; 2017; 12(4):e0175030. PubMed ID: 28384182 [TBL] [Abstract][Full Text] [Related]
52. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263 [TBL] [Abstract][Full Text] [Related]
53. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Milanov P; Ivanciu L; Abriss D; Quade-Lyssy P; Miesbach W; Alesci S; Tonn T; Grez M; Seifried E; Schüttrumpf J Blood; 2012 Jan; 119(2):602-11. PubMed ID: 22031860 [TBL] [Abstract][Full Text] [Related]
54. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684 [TBL] [Abstract][Full Text] [Related]
55. Clinical gene transfer studies for hemophilia B. High KA Semin Thromb Hemost; 2004 Apr; 30(2):257-67. PubMed ID: 15118937 [TBL] [Abstract][Full Text] [Related]
57. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Rawle FE; Lillicrap D Semin Thromb Hemost; 2004 Apr; 30(2):205-13. PubMed ID: 15118932 [TBL] [Abstract][Full Text] [Related]
58. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752 [TBL] [Abstract][Full Text] [Related]
59. AAV-mediated gene transfer for hemophilia. High KA Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424 [TBL] [Abstract][Full Text] [Related]
60. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]